Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00453362
Status:
COMPLETED
Last Update Posted:
2017-03-31
First Post:
2007-03-26
Brief Title:
A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
Pilot Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib
Status:
COMPLETED
Status Verified Date:
2011-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single-arm open-label multicenter international pilot study to evaluate changes that occur in 2-deoxy-2-18Ffluoro-D-glucose FDG- and 3-deoxy-3-18FfluorothymidineFLT-PET Positron Emission Tomography imaging as a result of treatment with erlotinib in patients with recurrent or refractory non-small cell lung cancer NSCLC The study will enroll approximately 30 patients at approximately 4 sites in Australia and 2 sites in the United States
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ML20773 | None | None | None |